On April 11, 2025, at the highly anticipated 2025 Wuzhen Health Conference, Frost & Sullivan, a global top growth consulting firm, won the 'China Famous Brand' awarded by Xinhua News Agency for its outstanding innovation practices in the three dimensions of 'technology integration, industry linkage, and brand co-creation'. Top Value Brands with Cross-border Integration for 2025 "This honor is not only a high recognition of Frost & Sullivan's leadership in the field of cross-border integration but also an authoritative affirmation of its role in promoting the deep integration of the health industry with resources from multiple sectors and building a high-quality development ecosystem."   Cross-border: Transforming Traditional Consulting and Leading Digital Transformation As a global leader in the consulting industry, Frost & Sullivan has always focused on technological innovation as its core driving force, dedicated to leading the digital transformation of the traditional consulting industry. By introducing advanced technologies such as AI, large models, and cloud computing, and innovatively proposing the 'Artificial Intelligence Empowered, Blockchain Technology Supported Knowledge Services (ABCK)' solution, Frost & Sullivan has taken the lead in deeply integrating knowledge services with digital tools in the industry. This has solved the pain points of 'information silos' and 'repeating the same wheel' in the traditional consulting industry, significantly improving service efficiency and accuracy. It is worth mentioning that as a professional research institution, Frost & Sullivan is also actively committed to providing high-quality research and consulting services for brands and society in the AI era. Frost & Sullivan cultivates industry-academia talents through open-source research and collaboration with universities, providing high-quality data support for large model training. At the same time, Frost & Sullivan is also actively involved in the formulation and promotion of industry standards, promoting the healthy development of AI technology. It hopes that through its own efforts, it can help brands build a clean online environment and a knowledge Great Wall in the AI era, enhancing the value and influence of brands.   Link: Delve into industry research to inspire cross-border wisdom Frost & Sullivan has been deeply involved in industry research for over 60 years, accumulating more than 10,000 original industry research reports and white papers in China. It spans across 19 core national economic industries and more than 6,000 sub-markets, providing in-depth analysis and trend predictions for various industries. In addition, Frost & Sullivan has published textbook-level publications such as 'White Paper on the Development Trends of China's Industries over the Next 50 Years', 'Investment Activity Report on the Issuance of 18A Biotech Companies in Hong Kong Stock Market', 'White Paper on the Development of Artificial Intelligence Industry in Hong Kong Stock Market', 'Hong Kong IPO and Secondary Market White Paper', and 'ESOP Equity Incentive Professional Plan' for many consecutive years in China. It has also cooperated with authoritative organizations including the China Academy of Information and Communications Technology, the Boao Forum for Asia Global Health Forum, and the Shanghai Stock Exchange to publish several industry white papers. In the field of life sciences, Frost & Sullivan maintains high-frequency and regular in-depth research outputs, releasing a large number of heavyweight industry white papers and blue papers every year, which have gained wide recognition from the capital market, industry, and investment community. From 2022 to 2024, it published three consecutive years with the 'Investment Activity Report on the Issuance of 18A Biotech Companies in Hong Kong Stock Market' (which includes not only 18A biotech companies in Hong Kong but also analyzes domestic science and technology innovation board biotech companies and those planning to go public), earning widespread praise from the industry for its influence and dissemination power.   Frost & Sullivan has also been actively advocating for industry integration, building cross-field dialogue bridges, and stimulating cross-border wisdom through its high-end exchange platforms such as the Frost & Sullivan Summit, which has been held in China for nearly 20 consecutive years and has been running continuously for nearly 30 years globally. Since 2022, Frost & Sullivan has hosted the New Investment Summit Forum in Life Sciences in China. Over the years, it has gathered more than 100 industry leaders, senior executives from biopharmaceutical companies, medical device companies, investment institutions, and professional service organizations, attracting over 1,000 professional attendees to jointly discuss new investment cooperation models, build a closer, more efficient, and win-win cooperation network, and jointly promote the vigorous development of the domestic and international life science industries. To this day, the Frost & Sullivan Summit has become an important platform for outstanding domestic enterprises, the investment community, and regulatory authorities to exchange successful experiences and jointly discuss development directions, as well as an important window for the world to understand China's most cutting-edge development trends.   Increment: Collaborating with authoritative institutions to drive brand growth Frost & Sullivan places great emphasis on and actively participates in the construction of 'Brand Powerhouses'. It has carried out in-depth strategic cooperation with highly influential institutions at home and abroad such as Xinhua News Agency's 'China Famous Brands', CCTV-1's 'Big Country Brands', and Forbes China Group, to jointly explore the value of Chinese enterprises and assist in the growth of Chinese brands. By integrating global resources with local insights, Frost & Sullivan has established a market position validation system and innovatively proposed the 'FSBVFrost & Sullivan Brand Value Model'. It has provided market position validation and brand valuation services to over 1,000 enterprises, continuously helping a large number of Chinese brands achieve growth strategies both domestically and overseas.   Frost & Sullivan: Crossing Boundaries to Create TOP Value Brands Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan Greater China, stated that we highly agree with the concept of 'cross-border integration, connectivity, and incremental value' proposed by Xinhua News Agency “China Famous Brands&rdquo., and will continue to promote the deep integration of the health industry with resources from multiple fields through innovative practices and professional services. This award for '2025 Cross-Border Integration TOP Value Brand' signifies that Frost & Sullivan's outstanding achievements in the field of cross-border integration have been highly recognized by the industry and market. In the future, Frost & Sullivan will continue to use technology as the engine, connectivity as the bond, and brands as the cornerstone to continuously empower the high-quality development of the health industry and contribute professional strength to building a new ecosystem of cross-border integration!  

2025 Wuzhen Health Conference   On April 11, 2025, the Wuzhen Health Conference —— Health Industry Innovation Forum was held in Wuzhen. With the theme of "Cross-border, Linking, Incremental," the forum aimed to aggregate rich ecological resources from various industries, cross-border integrate with China's health industry, and create a benchmark for leading high-quality innovation and development in China's health industry.   Wang Chenhui, Partner-in-Chief and President of Frost & Sullivan Greater China, Co-founder and President of LeadLeo, was invited to attend the forum. In his keynote speech titled "Content Marketing in the New Era of Technology: AI Marketing," he stated that 2025 is the first year of AI search, and there will be a good dividend period in the next 3-5 years. Under the wave of AI, by integrating authoritative reports and multimodal distribution strategies, brands can optimize their content adaptation and exposure in AI search, enhancing their influence in the era of AI search. Wang Chenhui Wang Chenhui   AI technology reshapes content marketing: from passive response to active intelligence Wang Chenhui pointed out that traditional AI relies on rule-driven and structured data, limited to specific task scenarios. However, large model technology breaks through domain limitations through large-scale pre-training and parameter sharing, achieving "active interaction." The new generation of AI represented by GPT-4 not only has multimodal understanding capabilities but can also generate high-quality text, images, and even complex reasoning results based on user needs.   “AI search extends from text to images, videos, voice, and integrates with smart wearables to achieve full-scenario interaction; future searches will be more intelligent, creating new opportunities for brands to reach consumers precisely.” He cited examples where e-commerce platforms can analyze user behavior through large models to achieve precise push notifications. Based on this, interactions between brands and users will also develop in a more efficient and personalized direction, further enhancing user experience and brand influence.   Breaking the information pollution dilemma: LeadLeo builds a credible data ecosystem Facing the problem of false content proliferation caused by information explosion, Wang Chenhui pointed out that “to promote the healthy development of information dissemination in the new era of AI, building an authoritative content screening and full-chain monitoring mechanism is a key measure to suppress the spread of false information and consolidate user trust.”   LeadLeo made forward-looking arrangements, opening its corpus since 2022, becoming one of the first domestic large model training data providers, and cooperating with authoritative platforms such as Wantu and Choice to incorporate professional reports into the knowledge source of large models, taking the market lead in advance. “LeadLeo's reports are highly professional, relying on industry-university-research cooperation with top universities such as Peking University, Tsinghua University, and Fudan University to continuously produce cutting-edge research, ensuring the authority and credibility of content.” Wang Chenhui said.   LeadLeo 5.0 era: A leader in AI-driven industry research transformation “LeadLeo's evolution from 1.0 to 5.0 era has gradually built a foundation for industry research, promoted technological innovation and collaborative development, and ultimately led the AI-driven industry research transformation.”   Wang Chenhui pointed out that since its official establishment in the 1.0 era in 2018, LeadLeo has built basic industry and enterprise research databases; entered the 2.0 era, promoted data platform inclusion and standardized product development, improving the level of research; in the 3.0 era, established an institute and expanded technology and education sectors to achieve multi-field collaboration; entered the 4.0 era, gained recognition from society and government, and won the deep trust of investors and readers; in the 5.0 era, deeply integrated AI technology, LeadLeo will continue to produce authoritative content and lead the digital industry research process.   Future outlook: Intelligent search reconstructs brand and user connections At the end of his speech, he called on the industry to embrace AI transformation, “2025 is in the cycle of updating large model training data. If enterprises can complete high-quality content layout during this period, they will lock in a cognitive dividend for 3-5 years.”   Wang Chenhui emphasized that LeadLeo's practice of deeply integrating authoritative reports and AI technology will continue to provide the industry with traceable authoritative content, helping brands achieve efficient reach and user trust building in the era of AI search, and jointly promoting the information ecosystem to evolve towards transparency and intelligence.   “With LeadLeo AI content marketing, brands can achieve precise and stable natural traffic acquisition and marketing ROI improvement, seize the opportunity in AI search, and form long-term competitiveness.”

Frost & Sullivan insight OpenAI, once a champion of closed-source development, has now turned its attention to open-source projects. On April 1st, Sam Altman, CEO of OpenAI, announced on the social media platform X that the company will release a "powerful new open-weight model" within the coming months. After years of adhering to a closed-source approach, OpenAI is re-examining the value of open-source. What are the motivations behind big companies choosing open-source models? Is it to build an ecosystem, attract developers, or to foster technological iteration through community feedback? Will multi-modal model open-source lead to the emergence of DeepSeek within the multi-modal space? What are the particularities of multi-modal models compared to text generation? How should we evaluate the current open-source ecosystem for multi-modal models? What are the main challenges that need to be overcome in current multi-modal large models? How can open-source promote the refinement and maturity of technology? Which industries might benefit from the open-source of multi-modal models?   Tran Cui, Executive Director of Frost & Sullivan Greater China, was interviewed by 21st Century Business Herald to discuss the construction of the ecosystem and industry opportunities under the wave of multi-modal model open-source. 21st Century Business Herald *Click at the end of the article Read the original article for a complete report     Q: What are the motivations behind big companies choosing open-source models? Is it to build an ecosystem, attract developers, or to foster technological iteration through community feedback? Tran Cui Executive Director of Frost & Sullivan Greater China   Firstly, big companies' open-source of multi-modal models will build a three-dimensional ecosystem that includes developer communities, hardware adaptation solutions, and industry application cases. Such an ecosystem construction will lower the entry threshold for developers, enabling them to quickly get started and innovate. With the development of the ecosystem, technology will advance rapidly and explore the application possibilities of multi-modal models in more scenarios, laying a solid foundation for future commercialization.   In addition, open-source has a deeper meaning, which is to promote the popularization and democratization of technology. Big companies have lowered the threshold for users to enter the multi-modal model field through open-source, allowing more small and medium-sized enterprises and developers to use advanced technology at a lower cost. This inclusiveness of technology not only accelerates the penetration rate of AI technology but also injects vitality into the rapid development of the entire industry.   At the same time, open-source also reflects the social responsibility of big companies. By open-sourcing, big companies are actually paving the way for future technical standardization. This open attitude not only makes technology more transparent but also helps with the healthy development of the industry.   Q: Will multi-modal model open-source lead to the emergence of DeepSeek within the multi-modal space? Tran Cui Executive Director of Frost & Sullivan Greater China   Under the trend of multi-modal model open-source, enterprises like DeepSeek are expected to stand out. These enterprises, with their advantages in technology, cost-effectiveness, open-source strategy, and ecosystem construction, will emerge in the market and drive progress in the entire field of multi-modal large models.   Q: What are the particularities of multi-modal models compared to text generation? How should we evaluate the current open-source ecosystem for multi-modal models? Tran Cui Executive Director of Frost & Sullivan Greater China   Firstly, compared to text generation models, multi-modal models need to handle various types of data such as text, images, audio, and video, while text generation models mainly handle text data. This characteristic of diverse data processing makes the application scenarios of multi-modal large models more extensive, such as environmental perception and decision-making in intelligent driving, and diagnostic assistance in medical imaging. In addition, multi-modal models are more complex in technical implementation and need to solve problems such as alignment and fusion between modalities. For example, how to effectively combine visual information in images with semantic information in text to achieve accurate understanding and generation. Therefore, multi-modal models usually require larger computing resources and more complex training strategies. In summary, compared to text generation models, multi-modal large models have characteristics such as diverse data processing, extensive application scenarios, and technical implementation complexity.   Currently, the contribution of open-source communities to multi-modal models is increasing day by day. Developers and researchers share code, datasets, and research results through community platforms, accelerating the iteration and optimization of technology. This positive development has continuously led to breakthroughs in the performance of multi-modal large models, gradually narrowing the gap with closed-source models, and even surpassing them in some aspects. At the same time, their application scenarios are also constantly expanding, covering multiple fields such as image generation, video editing, and voice interaction.   Q: What are the main challenges that need to be overcome in current multi-modal large models? How can open-source promote the refinement and maturity of technology? Tran Cui Executive Director of Frost & Sullivan Greater China   Currently, multi-modal large models face challenges in data processing and alignment. Due to the heterogeneity of multi-modal data, there are differences in format, dimensionality, and statistical properties among different modalities, making data fusion and processing complex. In addition, data from different modalities may have complex associations at the time, space, and semantic levels, thus triggering challenges in modal alignment and fusion during training, as well as problems such as "catastrophic forgetting" of language ability. Therefore, training multi-modal large models not only requires a large amount of computing resources but also has long training times and low efficiency.   However, open-source initiatives have lowered the usage threshold for multi-modal large models, enabling more developers and enterprises to access and apply advanced technology. This change has not only promoted the spread of technology but also enriched data resources and improved data quality as an opportunity. These improvements help train better models and further promote the refinement of technology.   Q: Which industries might benefit from the open-source of multi-modal models? Tran Cui Executive Director of Frost & Sullivan Greater China   The open-source of models will greatly promote the development of multiple industries. By providing high-quality capabilities such as video generation, voice interaction, and image generation, these models will bring innovation and efficiency improvements to multiple fields such as film and television entertainment, intelligent vehicles, education, autonomous driving, finance, logistics, healthcare, entertainment creativity, office tools, social entertainment, and legal consulting. *This interview has been published in 21st Century Business Herald. The reporter is Dong Jingyi, and the original title is: "Tearing off the Closed-Source Label! OpenAI 'Testing the Waters' with Open-Source, a Counterattack or Compromise?"

at 3 month 22 held on 2025 At the Frost & Sullivan China Entrepreneur Annual Conference and the Forbes China Industry Development Pioneer Awards Ceremony, Frost & Sullivan ( Frost & Sullivan Wang Chenhui, Managing Partner & President of Frost & Sullivan Greater China, delivered a speech on 'Content Marketing in the New Technology Era'. AI The wonderful speech in "Marketing", which delved into AI The profound impact of technology on industry development, as well as the role of brands in AI Strategies for responding to the times.   Wang Chenhui, Partner-in-Chief and President of Frost & Sullivan Greater China Region   AI Large models drive content marketing transformation   Wang Chenhui pointed out that since this year's Spring Festival, terms such as 'artificial intelligence' have once again become industry buzzwords, with large models making significant progress in reinforcement reasoning capabilities, computing power, and multimodal integration. Especially the addition of networking functions has made ordinary consumers feel the convenience and personalization of large model tools, driving a substantial increase in the daily and monthly active users of related tools. However, traditional PGC (professional-generated content) and UGC (User-generated content) models still face challenges in terms of information rigor and data pollution. In AI era, combine PGC high-quality works and UGC The rapid response capability enables the creation of more excellent content. It effectively conveys professional knowledge and information that was previously difficult for ordinary consumers to access to end customers, thereby promoting the progress of information production and circulation.   AI The Rise of Search and User Needs Satisfication   Wang Chenhui emphasized, AI Search is current. AI The fastest-growing area in the track industry. Compared to traditional search engines, AI Search can better identify user intent and help find more accurate information sources through search tools. Ordinary users often cannot delve into finding information when using traditional search engines due to limited energy. AI The inclusion allows users to view more references, providing stronger support for research. AI The popularization of search tools has met users' reliance on authority, avoidance of cognitive burden, and demand for efficiency improvement and immediate satisfaction. Consumers will AI Tools are regarded as your personal experts, and you want to directly access research results rather than reading obscure papers or reports. AI The development of technology, the future AI Search will be more diversified, not limited to web pages and APP It may also expand to various terminal devices such as smart cockpits, headphones, and glasses, changing people's search and communication habits.   Brand in AI Opportunities and Challenges of the Times   Wang Chenhui mentioned, AI The brand building of the times faces new opportunities and challenges. On one hand, through AI Search allows brands to reach target users more accurately, thereby enhancing brand awareness and influence. For instance, some brands optimize their content through AI The mention rate in the responses has seen a significant increase. On the other hand, AI The popularization of tools has also led to rapid information dissemination and the risk of data pollution. The release of bad content may cause damage to brands and categories. Therefore, brands need to strengthen underlying content defense to prevent false information from having a negative impact on brands and segments. Frost & Sullivan tests brands and categories on AI Performance in context, thereby helping brands understand their own AI Understand the cognitive environment and formulate corresponding content marketing strategies.   AI Marketing   Wang Chenhui suggested that brands AI The era adopts proactive and positive strategies to enhance brand influence. Firstly, brands need to attach importance to AI Search optimization is achieved by publishing high-quality, rigorous research reports and disseminating press releases through whitelist media to spread correct and authentic knowledge, thereby enhancing the brand's AI The mention rate and content authority in the answers. Secondly, brands should pay attention to AI The traceability of search results ensures the accuracy and credibility of brand information, namely 'certainty of rights, authenticity, and value'. In addition, brands can also enhance their brand reputation and authority by collaborating with professional research institutions, leveraging their expertise, industry reputation, and authority. AI Competitiveness in the environment. At the same time, brands need to pay attention AI The development trend of technology, timely 'health check-ups', adjusting marketing strategies to adapt to the ever-changing market environment, and building one's own knowledge fortress.     Frost & Sullivan's' AI The Mission and Action of the Times   Wang Chenhui said that as a professional research institution, Frost & Sullivan is committed to in AI The Times provides high-quality research and consulting services for brands and society. Frost & Sullivan cultivates industry-academia research talents through open-source research and collaboration with universities, providing high-quality data support for large model training. At the same time, Frost & Sullivan actively participates in the formulation and promotion of industry standards, driving AI The healthy development of technology.    Frost & Sullivan hopes to help brands in AI The era constructs a clear online environment and a knowledge Great Wall to enhance the value and influence of the brand.   At the end of his speech, Wang Chenhui called on leading brands and enterprises across all industries to take the lead in attaching importance to it AI Content marketing and brand building in the era, actively responding AI Opportunities and challenges brought about by technology. He emphasized that brands need to AI Build defensive barriers in the environment to prevent infringement of false information. At the same time, enhance brand influence through innovative marketing strategies and high-quality content output. AI Competitiveness in the Search Era. Wang Chenhui's speech for brands in AI The marketing and construction of the era have provided valuable guidance and inspiration, attracting widespread attention and discussion among participants.

Frost & Sullivan On March 22, 2025, the '2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor', co-hosted by Frost & Sullivan and Forbes China, was successfully held at the Shanghai Seagull Lijing Hotel.   At this grand event, a total of 21 outstanding experts and entrepreneurs in the medical field, 6 industry-leading enterprises, 2 influential institutions, an innovative brand, and an ESG benchmark were selected. These outstanding individuals and enterprises have demonstrated the vibrant vitality and development potential of China's medical industry with their exceptional innovation capabilities and relentless exploration spirit, painting a magnificent blueprint full of hope and dynamism for the future of the industry. Main Selection - 2025 Forbes China's Top Industry Development Leaders     Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan Greater China, and Professor Wang Yu, Expert Advisor to the Jury and Chairman of the Chinese Liver Disease Prevention and Control Foundation, presented awards to Jiang Mingyu, Executive Director, Vice President and Secretary of the Board of Directors of Tongyuan Kang.   ● Company Introduction Zhejiang Tongyuan Kang Medicine Co., Ltd. (TYK Medicines, Inc., stock code: 02410.HK) is a clinical-stage biopharmaceutical company focusing on cancer treatment, established in November 2017, headquartered in Huzhou, Zhejiang. The company is committed to developing small molecule targeted therapeutic drugs and possesses a small molecule drug design and screening platform, deuterated drug research and development technology platform, and macromolecular immunotherapy platform. Its core product, TY-9591, is a third-generation EGFR-TKI that is undergoing pivotal clinical trials. Tongyuan Kang Medicine successfully listed on the Hong Kong Stock Exchange on August 20, 2024, raising HK$579 million. The company plans to start operating its cGMP compliant production facility in Huzhou in the first quarter of 2025, with a designed annual production capacity of about 150 million tablets or capsules. In the future, the company will promote the commercialization of its core products through internal efforts and external cooperation, as well as expand the global market.   Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan's Greater China Region, and Professor Wang Yu, an expert advisor to the judging panel and Chairman of the China Hepatitis Prevention and Control Foundation, presented awards to Xiang Gongwei, Chairman of Inner Mongolia Otterchi Mongolian Medicine Co., Ltd.   ● Company Introduction Inner Mongolia OTCHIMON Pharmaceutical Co., Ltd. is a national high-tech enterprise, with more than ten subsidiaries including Ulanhot Zhongmeng Pharmaceutical Co., Ltd., Hohhot Jinshan Mongolian Medicine Factory, Inner Mongolia OTCHIMON Pharmaceutical Co., Ltd., Beijing Rangfeng Pharmaceutical Co., Ltd., and Xing'an League OTCHIMON Agricultural Resources Development Co., Ltd. It has formed a new development system for the entire Mongolian medicine industry chain, integrating Mongolian medicinal material planting, research and development, production, sales, and modern pharmaceutical logistics. Over the years, with the strong support of Party committees and governments at all levels, the company has made significant progress. It is now one of the Mongolian medicine production enterprises with the largest scale of infrastructure construction, the largest number of exclusive intellectual property Mongolian medicines, the most Mongolian medicine trade names, the widest sales network coverage, the largest market scale, the largest number of Mongolian medicines included in the national medical insurance catalog, and the earliest establishment of factories.   Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan's Greater China Region, and Professor Wang Yu, an expert advisor to the judging panel and President of the China Foundation for the Prevention and Control of Hepatitis, presented awards to Li Ding, Chief Technology Expert of Shaanxi Yun.   ● Company Introduction Shaanxi Yungu Zhonghui Biopharmaceutical Co., Ltd. is an innovative enterprise focusing on the biomedical field, dedicated to researching, developing, producing, and selling high-quality biopharmaceutical products. The company focuses on the application of biotechnology in the pharmaceutical industry, promoting the development of the health industry through technological innovation and rigorous quality control, and providing advanced biomedical solutions to customers worldwide.   Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan Greater China, and Professor Wang Yu, Expert Advisor of the Jury and Chairman of the China Foundation for the Prevention and Control of Hepatitis, presented awards to Cai Jiangnan, Executive Chairman of Shanghai Chuangqi Health Development Research Institute.   ● Company Introduction The Shanghai Chuangqi Healthy Development Research Institute is established within the field of big health, aiming to promote in-depth exchanges and learning among industries, academia, government, investment, and media by connecting policy systems, technological development, and business models. It aims to create a platform that helps value innovation in the health industry and sustainable growth for leaders. The institute is guided by the Shanghai Health Commission. In 2019, Professor Cai Jiangnan, an expert in health economics and health policy, as the founder, with the support of government leaders, academic experts, industry leaders, and practitioners in the field of big health, joined forces with Professor Hu Shanlian from the School of Public Health at Fudan University, Professor Yu Wei from the School of Public Economics and Management at Shanghai University of Finance and Economics, and Professor Song Chengli from the School of Medical Devices and Food at ShanghaiTech University to promote the establishment of the institute. Adhering to the mission of 'Intelligent Leadership, Health Innovation, Value Creation', the institute conducts research consultations, learning exchanges, and conferences and forums around three levels: policy systems, industrial innovation, and technological development. By empowering leaders in the health industry, it aims to promote the renewal and upgrading of management capabilities in China's health industry; by building bridges between advanced domestic and international research achievements and market applications, it promotes value enhancement and innovation in the field of big health.   Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan Greater China Region, and Professor Wang Yu, an expert consultant to the judging panel and President of the Chinese Hepatitis Prevention and Control Foundation, presented awards to Chen Wei, Chairman and General Manager of Shanghai Zhongke New Life Biotechnology Co., Ltd.   ● Company Introduction Shanghai Zhongke New Life Biotechnology Co., Ltd. was established in 2004, originally as the external service platform of the Proteomics Research and Analysis Center at the Shanghai Institute of Life Sciences, Chinese Academy of Sciences. The company has formed an enterprise innovation research institute through technical cooperation with domestic and international research institutions and the innovative capabilities of its own R&D team. It has established four major technical platforms: a large-scale array multi-omics research technology platform, a preclinical CMC research and analysis platform for biopharmaceuticals, a platform for the registration and approval of biopharmaceuticals and medical devices, and an AI big data algorithm platform. The company has deployed three business segments: technology services, biomedicine, and consumer healthcare CRO services for the large health industry, constructing a business blueprint for life science and health that combines AI big data with mass spectrometry multi-omics technology applications.   Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan's Greater China Region, and Professor Wang Yu, an expert advisor to the judging panel and President of the Chinese Hepatitis Prevention and Control Foundation, presented awards to Huang Yuanyu, Chairman and Chief Scientific Officer of Suzhou Xuanjing Biotechnology Co., Ltd.   ● Company Introduction Suzhou Xuanjing Biotechnology Co., Ltd. and Beijing Xuanjing Rui Medicine Technology Co., Ltd. were established in 2022. The company focuses on the research, development, and industrialization of innovative small nucleic acid drugs, aiming to be a pioneer and disruptor in the field of nucleic acid pharmaceuticals. The company has gathered a core team with over 10 years of industry experience, possessing rich expertise in various aspects such as nucleic acid biology, nucleic acid chemistry, hepatic and non-hepatic delivery, project management, pharmaceutical research, registration and application, clinical development, etc. The company has established a global independent intellectual property system (RIHOST) targeting key technical bottlenecks, intellectual property barriers, and future development directions in this field. ® RICMO ® LICOD ® The core technology platform has established multiple in vivo delivery technologies for non-liver tissues based on various exclusive strategies, making it a global leader in the research and development of non-liver delivery technologies and pipelines. The company has a profound understanding and differentiated considerations in target and indication selection. Liver-targeted products have already entered clinical research, and the development of a series of small nucleic acid drugs for non-liver tissues will be rapidly advanced to bring benefits to patients.   Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan Greater China, and Professor Wang Yu, an expert advisor to the judging panel and President of the China Hepatitis Prevention and Control Foundation, presented awards to Zhang Danni, Co-founder of Shuimu Future.   ● Company Introduction Shuimu Future (Beijing) Technology Co., Ltd. is a new type of drug R&D platform company driven by A1+ cryo-electron microscopy. Based on core technologies such as structural biology, deep learning, and high-performance computing, the company promotes digital innovation in drug R&D in areas such as small molecules, antibody drugs, protein degradation, and gene therapy, helping global innovative pharmaceutical companies significantly improve their drug R&D efficiency and success rate.   Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan's Greater China Region, and Professor Wang Yu, an expert consultant to the judging panel and Chairman of the Chinese Liver Disease Prevention and Control Foundation, presented awards to Song Ning, Chairman and General Manager of Hangzhou Desheng Biotechnology Co., Ltd.   ●  Company Introduction Hangzhou Deshi Biotechnology Co., Ltd. was established in 2016 and is a global leader in medical imaging AI and medical imaging equipment. It has seven subsidiaries and branches in countries and regions such as Singapore. The company is led by several national experts who oversee R&D, production, and sales teams. More than 50% of the R&D team has a master's degree or above and over 10 years of experience in the medical industry. The company has successively presided over and participated in several national and provincial-level scientific research projects, including special projects of the National Key Research and Development Program, and has created the world's largest medical imaging general large model with the largest parameter scale. It holds more than 60 core independent intellectual properties in multiple fields such as prenatal diagnosis, assisted reproduction, blood tumor diagnosis, and radiological health in China, the United States, Europe, and other places. The company has established a Zhejiang Provincial Enterprise R&D Center, training and exhibition center, a GMP production workshop with a capacity of 100,000 to 1 million units, mold processing and 3D printing workshops, etc. In 2019, it successfully released the world's first chromosome intelligent analysis system (AutoVision) based on AI technology. ® ) and its high-precision scanning equipment (MetaSight ® In 2023, it won the certification of 'International First-Generation Equipment' from relevant government departments, and its market share of several core medical products has been steadily increasing.   Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan Greater China, and Professor Wang Yu, an expert advisor to the judging panel and Chairman of the China Hepatitis Prevention and Control Foundation, presented awards to Wang Junqi, Chairman and CEO of Jingzhi Future.   ● Company Introduction Jingzhi Future (Guangzhou) Intelligent Technology Co., Ltd. is a global leader in the field of breath testing, a national high-tech enterprise, one of the first projects signed for the Disruptive Technology Innovation Fund, and a recipient of the "National Disruptive Technology Innovation Key Special Project." Its products have been selected for the National "13th Five-Year Plan" Science and Technology Innovation Achievements Exhibition. Relying on its independently developed "Microelectromechanical (MEMS) + Microfluidic + Artificial Intelligence (AI)" integrated technology, the company has successfully launched the world's first chip-based breath molecular analysis micro gas chromatograph. It can accurately perform qualitative and quantitative analysis of volatile organic compounds (VOC) in human breath, with a detection sensitivity reaching the ppt level (one trillionth), breaking international monopolies and realizing the bedside, intelligent, and low-cost development of breath metabolomics testing equipment. Currently, this product has obtained Class II innovative medical device certification and has been implemented first in physical examination centers and community health scenarios. In the future, it can cover areas such as early cancer screening, rapid disease diagnosis, and home monitoring of chronic diseases, providing a new non-invasive, convenient, and inclusive disease diagnosis and management solution.   Dr. Wang Xin, Global Partner at Frost & Sullivan and Chairman of the Greater China Region, and Professor Wang Yu, an expert advisor to the judging panel and Chairman of the Chinese Hepatitis Prevention and Control Foundation, presented awards to Zhu Shu, Founder/Chairman of Hefei Han Microbial Technology Co., Ltd.   ● Company Introduction Hefei Han Microbial Technology Co., Ltd. is the first domestic company to deeply explore the gut-brain axis, integrating natural microorganisms, metabolites, and synthetic biology. Han Microbial focuses on developing live bacterial drugs and small molecule drugs based on natural microbial metabolites as its core business. It has developed breakthrough therapies based on microorganisms for various immune and neurological diseases such as inflammatory bowel disease, IgA nephropathy, depression, and Parkinson's disease.   Dr. Wang Xin, Global Partner at Frost & Sullivan and Chairman of the Greater China Region, and Professor Wang Yu, an expert consultant to the judging panel and Chairman of the China Hepatitis Prevention and Control Foundation, presented awards to Chen Yuxin, Chairman and CEO of Jiangsu Pule Medicine Biotechnology Co., Ltd.   ● Company Introduction Jiangsu Pulai Pharmaceutical Biotechnology Co., Ltd. was established in April 2009 and is a high-tech biopharmaceutical enterprise focusing on the research, development, and production of peptides and small molecule drugs. The company is located in the High-tech Development Zone of Jiangyin City, Jiangsu Province and is a national high-tech enterprise. It has wholly-owned R&D subsidiaries, Changchun Pulai Pharmaceutical Biotechnology Co., Ltd. and Nanjing TinoV Pharma Technology Co., Ltd., as well as subsidiaries Jiangsu Pulpe Pharma Technology Co., Ltd., Pulai Medical Holdings (Hong Kong) Co., Ltd., and Pulai Pharma (Australia) Co., Ltd.   The company's core development strategy is centered around innovative drug research, development, and production. It has established a variety of first-in-class peptide and small molecule new drug R&D pipelines led by national Class 1 anti-infection, anti-tumor, autoimmunity, and metabolic new drugs. The company currently holds dozens of patents, including PCT international invention patents, US and EU invention patents, Chinese invention patents, utility model and design patents, etc.   Since its establishment, the company has undertaken more than 40 scientific research projects, including major national science and technology projects such as the 12th Five-Year Plan and 13th Five-Year Plan 'Major New Drug Development', and the National 'Scholarly Exchange Students' Science and Technology Innovation and Entrepreneurship Project Selection Fund.   In the future, based on its existing antibacterial peptide series products, the company will continue to prioritize research and development alongside production and operation. It will explore the market with high-quality innovative products, striving to become a leader among international antibacterial peptide pharmaceutical enterprises!   Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan's Greater China Region, and Professor Wang Yu, an expert advisor to the judging panel and President of the Chinese Liver Disease Prevention and Control Foundation, presented awards to Zhang Dan, co-founder and co-chairman of Jiangsu Puxin Biopharmaceutical Co., Ltd.   ● Company Introduction Puxin Biotech, positioned as a global provider of integrated solutions for cell therapies, has its headquarters in Wuzhong District, Suzhou City, on the beautiful shores of Taihu Lake. It owns a Suzhou headquarters (10,000㎡ GMP factory building and R&D center) and an European headquarters in Liege, Wallonia region of Belgium, achieving global supply of cell preparations. Puxin Biotech focuses on the field of cell therapies and has established a dedicated HiPlasTM vector system and HiLenti for different types of cell therapies such as CAR-T, TCR-T, CAR-NK, TIL, and HSC. ® Suspension Serum-Free Virus Production Platform and HiCellx ® A cell process development platform with high transduction efficiency and a quality control platform. The platform has supported multiple partners in successfully incubating various drugs such as CAR-T, TCR-T, CAR-NK, and HSC, totaling more than 10 clinical approval documents from regulatory agencies including NMPA, EMA, and FDA, and has facilitated the conduct of multiple international multi-center clinical trial projects.   Dr. Wang Xin, Global Partner at Frost & Sullivan and Chairman of the Greater China Region, Professor Wang Yu, an expert advisor to the judging panel and President of the China Hepatitis Prevention and Control Foundation, presented the award to He Ruyi, Chief Scientist at CIC Healthcare.   ● Company Introduction Guotou Innovation (Guotou Investment & Merchants) focuses on investment in advanced manufacturing industries, values technological innovation, outstanding entrepreneurs, and team values. It particularly invests in fields such as intelligent manufacturing, new energy intelligent vehicles, life sciences, information and communication technology, etc., aiming to promote the green, digital, and service-oriented development of manufacturing. The team has managed assets of nearly 100 billion RMB in total, with investors including financial institutions, social security funds, state-owned and private capital.   Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan's Greater China Region, and Professor Wang Yu, an expert advisor to the judging panel and President of the Chinese Liver Disease Prevention and Control Foundation, presented awards to Ding Zhenhu, Chairman of Anhui Zhongji Guoyi Medical Technology Co., Ltd.   ● Company Introduction Anhui Zhongji Guoyi Medical Technology Co., Ltd. was established in January 2016 and is a pioneer and leader in the domestic medical supplies SPD smart supply chain. The company takes serving the high-quality development of Chinese hospitals as its mission and has pioneered the domestic third-party pure service model for SPD and the city-wide medical supplies smart management service center (CMS). Since its establishment, it has received capital injections from investors such as Hefei State-owned Assets Supervision and Administration Commission, Jifu Venture Capital, Xinli Capital, iFlytek, Qianhai Fund, Anhui Railway Fund, etc., and has introduced GF Securities, planning to go public as a whole in 2026.   Wang Chenhui, Partner-in-Chief and President of Frost & Sullivan Greater China, presented awards to Jinhua Jun, Founder, Chairman, CEO & CTO of Shanghai Jun Sai Biotechnology Co., Ltd.   ● Company Introduction Jun Sai Biotech is committed to the development of innovative drugs and therapies for tumor infiltrating lymphocytes (TIL). Through recognition as a national high-tech enterprise and a specialized, refined, characteristic and innovative small and medium-sized enterprise in Shanghai, it has received the 'Shanghai May 1st Labor Medal' and developed into a leading enterprise in the field of TIL therapy in China. The company has independently established the internationally leading DeepTIL. ® Cell expansion and NovaGMP ® The company has developed a gene modification technology platform and a series of globally leading TIL cell drugs based on this platform. GC101, the world's first natural TIL therapy without chemoembolization or IL-2 injections, which is currently in pivotal Phase II clinical trials, and GC203, a non-viral vector gene modification TIL therapy in Phase I clinical trials, have demonstrated excellent clinical efficacy in the treatment of more than 10 different types of advanced solid tumors, leading in clinical progress domestically. The company's core technology has been deployed in nearly 50 Chinese invention patents and international PCT applications, and has received funding for 9 special projects from national-level bodies, Shanghai Science and Technology Commission, Development and Reform Commission, etc.   The 2025 Forbes China Industry Development Pioneer Awards Ceremony   Wang Chenhui, Partner-in-Chief and President of Frost & Sullivan Greater China, and Guo Junyi, General Manager of Business Operations at Forbes China Group, jointly presented awards to representatives of the 2025 Forbes China Industry Development Pioneer Companies. Recipients include Li Zhan, Chairman of Anhui Zesheng Technology Co., Ltd., Liang Wenqing, Chairman and CEO of Changfeng Pharmaceutical Co., Ltd., Qu Chao, Founder and Vice Chairman of Pelt Medical Technology Co., Ltd., Li Zhi Le, Director, Chief Financial Officer, Board Secretary, and President of Pelt America of Shanghai Mengke Pharmaceutical Co., Ltd., Jiao Peng, Chairman and CEO of Bibo Biotech, and Guo Zhenyu, Chairman and CEO of Yunnan Baitai Biotechnology Group Co., Ltd.   ● Company Introduction Anhui Zesheng Technology Co., Ltd., as a national key “little giant” enterprise and high-tech enterprise focusing on specialized, refined, characteristic and innovative products, has achieved an all-round layout of its own brand portfolio “Annaiji”, “Sain Biomedical”, “3AMaterials”, “3ABio”, “3ASenrise”, covering the entire chemical industry chain and deeply involved in the fields of chemical reagents and pharmaceutical intermediates. The company focuses on industries such as medicine, semiconductors, and new energy, providing high-purity chemical raw materials and advanced material solutions, with products covering organic, inorganic, and equipment consumables. With outstanding independent innovation capabilities and strict quality control, it has built a global sales network and cooperated closely with leading enterprises in the industry. The company continues to increase investment in research and development, holds multiple core patents, and is committed to becoming a global leading supplier in niche fields.   ● Company Introduction Changfeng Pharmaceutical is a global emerging leader in inhalation delivery technology, focusing on the treatment of respiratory diseases. The company's mission is to develop innovative therapies to help patients breathe better. As one of the few companies worldwide that master the main inhalation formulations (the gold standard for treating respiratory diseases), the company has developed a rich portfolio of products. At the same time, the company actively explores innovative inhalation formulation dosage forms and extends its treatment areas to new disease areas, developing potential first-in-class or China-first-in-class treatments that comprehensively cover patients, medical specialties, and treatment areas. The company has obtained six product approvals from the National Medical Products Administration (NMPA) and the US Food and Drug Administration (FDA), and has achieved commercial success, demonstrating its strong capabilities in clinical development, production, regulatory affairs, and commercialization. Standing at the forefront of global innovation, the company is conducting global development of more than 20 candidate products in major markets such as China, the United States, Europe, emerging markets in Southeast Asia and South America, and more.   ● Company Introduction Panther Healthcare is a brand under Beijing Panther Medical Technology Co., Ltd. Panther Healthcare is a rapidly growing professional company rooted in China, focusing on the research, development, production, and sales of surgical instruments. The company was established in 2002 with its headquarters located in Beijing, covering more than 70 countries or regions across mainland China and overseas. In 2010, Panther Healthcare received investment from SoftBank China Venture Capital and became a foreign-invested enterprise. In May 2011, it was rated as a national high-tech enterprise. In January 2014, the company was ranked 90th among the most potential enterprises in China by Forbes magazine of the United States. After several years of rapid development, the company has become a leading brand among local stapler brands.   ● Company Introduction Mengke Pharmaceutical is an innovative biopharmaceutical company centered on the treatment of infectious diseases, with global independent intellectual property rights and international competitiveness. It is committed to discovering, developing, and commercializing innovative drugs for unmet clinical needs. Since its establishment, the company has always adhered to the philosophy of "seeking good efficacy with good drugs," focusing on the increasingly serious bacterial resistance problem globally. With solving clinical challenges and differentiated innovation as its core competitiveness, the company aims to become a respected leader in innovative drug development, providing patients with better differentiated treatment products. The company has established R&D centers in China and the United States and has an international core R&D team. The company's R&D team has many years of experience in international innovative drug research and management, having led or participated in the development of several marketed anti-infective new drugs. The company insists on independent research and development, delves into specialized niche areas, and has established an integrated antibacterial new drug R&D system within the company, covering the entire new drug development process including early design and screening of innovative drugs, preclinical evaluation, global clinical development, registration application, and production management. The company adopts the operational model of simultaneous new drug development in China and the United States with international experience and standards.   ● Company Introduction Bibo Biotech is one of the few CDMOs in the world capable of providing large-scale commercial production for biopharmaceutical companies. It has two R&D centers in Boston and Shanghai, as well as three GMP factories globally. The company has built multiple core technology platforms, including microbial fermentation, mammalian cell culture, XDC, and GMP production facility engineering customization services, providing customers with one-stop services covering the entire lifecycle of biopharmaceutical CMC.   Relying on PanFlex ® - Engineering technology. Bibo Biotech has built the world's first ultra-large-scale stainless steel mammalian cell production platform with a working volume of 30,000 liters per tank, and has achieved GMP production of biopharmaceutical products, filling a core technology gap in China's biopharmaceutical industry. It can provide the industry with a full range of production capacity solutions from 500 liters to 30,000 liters, helping customers gain comprehensive advantages in cost, product quality, and supply assurance.   The core team members of Bibo Biotech have experience leading over 130 projects, including 21 listed product projects, providing high-quality and efficient R&D and production services for numerous domestic and international partners. Driven by technology and demand, biopharmaceuticals are entering a fourth wave of biopharmaceutical manufacturing characterized by a 30,000-liter stainless steel bioreactor technology as the core, a total production capacity of one million liters as the foundation, and large-scale intensive production. As a leader in the fourth wave of biopharmaceutical manufacturing, Bibo Biotech independently designed the world's first 30,000-liter production platform and achieved an engineering and technological miracle of "Right on the First Time" and "Success on the First time" during the process of GMP production for biopharmaceutical products!   ● Company Introduction Yunnan Betaine Biotechnology Group Co., Ltd. was established in 2010 and is a large health industry group integrating R&D, production, and marketing, positioned for the skin health internet+. The company went public on the ChiNext of the Shenzhen Stock Exchange on March 25, 2021, with the stock code 300957, becoming the first stock of efficacy skincare products in China.   Sub-listing of Top 100 Chinese Industry Leaders by Forbes 2025 沙利文全球主管合伙人兼董事局执行董事祖亚儒（Aroop Zutshi）、福布斯中国集团商务运营总经理郭隽祎共同为2025福布斯中国行业发展领军企业——华熙生物颁奖   ● 企业介绍 ：华熙生物（688363.SH）成立于2000年，是一家合成生物科技创新驱动的生物科技公司，生物材料全产业链平台公司。公司致力于“提高生命质量、延长生命长度”。公司的使命是“让每个生命都是鲜活的”，希望为人类持续带来健康美丽、快乐的生命体验。在全球生物科技产业迅猛发展的大背景下，华熙生物一直基于自身产业优势不断推动生命科学的进步。公司从生物学基础研究出发，聚焦糖生物学和细胞生物学这两大基础学科，依靠合成生物领域的产业转化优势，为生命健康提供科学解决方案，并从生物材料的上游研发开始，从原料生产贯通到品牌建设，探索了一条生物材料全链路转化的路径。   2025福布斯中国行业发展领军企业颁奖现场   沙利文全球主管合伙人兼董事局执行董事祖亚儒（Aroop Zutshi）、福布斯中国集团商务运营总经理郭隽祎共同为2025福布斯中国行业发展领军企业依科赛生物科技股份有限公司、睿健医药iRegene、汉邦科技、深信生物（Innorna）颁奖。   ● 企业介绍 ：依科赛生物创立于2013年，以“加快生命科技应用，造福百姓健康”为使命，是国内生物制造上游领域关键原材料领军企业，是全球第五、国内最大胎牛血清生产商之一，国内首选GMP级别细胞基因治疗无血清培养基品牌，也是抗体培养基定制化和生物药质量检测试剂盒的领导企业，为生命科学研究和生物药产业赋能。公司是国家高新技术企业，国家级专精特新小巨人企业，中国首家国际血清行业协会（ISIA）会员单位，江苏省生物制药、细胞治疗等领域用CD无血清培养基工程研究中心、苏州质量奖企业。   公司依托国际化和专业化的研发技术团队、质量和生产团队以及商业化团队，持续创新，追求卓越，在不断优化产品性能的同时，确保可靠的质量和稳定的供应，其产品为国内外科研、生物药产业领域诸多头部客户广泛使用，全面赋能生物医药产业的快速健康发展，致力于成为全球生物制药和生命科学研究细胞培养工具的领导企业。   公司目前已服务超过10,000家客户遍布高校、研究所、医院、生物制药、基因测序等领域，在中国主要城市设有管理和营销中心，并在美国、澳大利亚和乌拉圭设有分公司。   ● 企业介绍 ：武汉睿健医药科技有限公司作为一家致力于成为全球领先的通用型化学诱导细胞治疗药物企业，是全球较早将“AI＋化学诱导”应用于细胞特定功能改造的Biotech公司。与基因治疗，及基因编辑疗法相比，该平台具有更为高效、安全、低成本且更适合大规模工业生产的优势。基于化学诱导这一独特平台，睿健医药建立了丰富的通用型细胞治疗产品管线，为以帕金森病为代表的神经退行性疾病、失明等“无法治愈”疾病开发通用型细胞治疗产品，带来治愈可能。   公司首款基于“化学诱导”平台研发的产品“人源多巴胺能前体细胞注射液NouvNeu001”已于2023年8月获得NMPA批准正式进入临床阶段，成为全球首个进入临床阶段的化学诱导iPSC衍生治疗产品，2024年6月也获得美国FDA开展海外临床，睿健也因此实现了全球首个人诱导多能干细胞（iPSC）衍生帕金森管线中美两地IND“双报双批”，更具有突破意义的是，睿健医药“化学诱导平台”在2024年3成为全球首个获得美国FDA特殊豁免资格的研发体系。面向早发型帕金森的第二款产品NouvNeu003也于2023年12月获得NMPA批准正式进入临床I期。目前，睿健的NouvNeu001和NouvNeu003均已完成Ⅰ期临床试验全部受试者入组给药，目前安全性、耐受性良好，并已顺利达成研究主要目的。此外，睿健医药的突破性眼科产品NouvSight001于2024年3月也被美国FDA授予孤儿药认定（ODD）。   到目前为止，睿健医药已成为国际iPSC领域获得监管机构认可最多，管线进展最快，治疗患者最多的领军企业，其独特的“化学诱导”细胞功能改造平台也在临床阶段进一步凸显出其独特优势，未来将会为患者带来更多突破性产品。   ● 企业介绍 ：汉邦科技是一家以色谱产品为核心的高新技术企业，主要为生物制药领域下游提供专业的分离纯化装备、耗材与技术服务。经过多年发展，公司形成了以小分子药物分离纯化装备、大分子药物分离纯化装备和实验室仪器设备为主的产品线，包括规格丰富、用途多样的各类分离纯化设备及配套设备、配件等，同时为客户提供制药工程下游分离纯化整体解决方案。   ● 企业介绍 ：深信生物于2019年创立，是一家递送技术平台型公司，主要从事核酸药物的递送技术开发，是国际范围内为数不多的掌握脂质纳米粒(LNP)底层技术的硬科技公司。深信生物拥有全球领先的具有自主知识产权的LNP递送技术，并在全球范围内进行了专利布局。   深信生物已与多家国内外生物医药公司达成合作，以共同开发或授权方式，使得更多的公司可以利用深信生物的LNP平台技术开发更多新型核酸药物。涉及的疾病领域包括罕见病、传染性疾病以及肿瘤等，部分管线已进入临床试验阶段。   子评选-2025福布斯中国行业发展影响力机构 2025福布斯中国行业发展影响力机构颁奖现场   福布斯中国集团商务运营总经理郭隽祎，沙利文合伙人兼中东、南亚、北非区总裁Robin Joffe共同为2025福布斯中国行业发展影响力机构代表颁奖。获奖机构：中国肝炎防治基金会、甫康（上海）健康科技有限责任公司、病痛挑战基金会。   ● 机构介绍 ：中国肝炎防治基金会是1996年6月由中国人民银行批准成立，1998年8月民政部注册登记的全国性公募基金会。2016年10月被民政部认定为慈善组织；2019年被民政部评为4A级社会组织。业务主管单位为国家卫生健康委员会，2022年7月由国家疾病预防控制局代管。业务范围包括：配合政府有关部门进行肝炎预防控制规划的实施，重点资助偏远、贫困地区开展肝炎防治工作；促进肝炎防治知识的传播与宣传动员；资助肝炎防治的科学研究，开展专业培训和技术咨询；组织开展肝炎患者互助互教交流活动；承接政府有关部门向社会组织购买服务的项目工作；推动国内、外友好往来，加强学术交流与合作。   中国肝炎防治基金会以“防治肝炎造福人类”为己任，以“积极募集资金与物资，开展公益活动，推动中国肝炎防治事业发展，提高全民族健康素质”为宗旨，落实“预防为主防治结合”的卫生健康方针，在民政部、国家卫生健康委员会、国家疾病预防控制局的领导下，积极募集资金与物资，在调查研究、建言献策、普及知识、推广干预模式、健康帮扶、人才培养、繁荣学术交流等方面充分发挥全国性公募基金会的作用。积极开展各类公益项目，直接惠及民众约1.1亿人次，是中国肝炎防治事业不可或缺的重要平台。   ● 机构介绍 ：甫康药业（Convalife Pharmaceuticals ）是一家立足中国、面向全球的处于临床阶段的新药研发企业，致力于在肿瘤、病毒和衰老疾病领域开发创新药物。甫康药业核心团队主要来自诺华、华海等国内外顶尖药企，与中科院上海药物所等国内外知名研究所持续合作。公司以中国及全球未满足的临床用药需求为导向，设计、研发具有“First-in-Class”或“Best-in-Class”潜力的原创新药，布局新一代双特异抗体生物药以及差异化小分子药物，为广大患者提供创新治疗方案。甫康药业肿瘤产品管线覆盖了乳腺癌、肺癌、胆管癌、前列腺癌、胰腺癌、胃癌等国内外急需创新治疗方案的实体肿瘤和血液肿瘤，包括已显示出“Best-in-Class”潜力的第二代PARP抑制剂CVL218，全球领先的PI3K β/δ双重高选择性抑制剂CVL237，还包括针对实体瘤的“First-in-Class”创新双特异性抗体等。甫康药业病毒产品管线包括针对多种传染性疾病进行药物研发，如新冠病毒、呼吸道合胞病毒、猴痘病毒、黄热病毒等。   ● 机构介绍 ：北京病痛挑战公益基金会（简称病痛挑战基金会，英文缩写ICF）是北京市第一家关注罕见病领域的公益基金会，致力于通过社群服务、行业支持、社会倡导，共同解决罕见病群体面临的迫切问题，为面临病痛挑战的人士，建立平等、受尊重的社会环境。本基金会缘起于“冰桶挑战”，于2016年2月29日国际罕见病日正式宣告成立。   ICF致力于支持罕见病病友的医疗康复、教育就业、社会融入等，培育积极行动的罕见病自组织，搭建多方参与的平台，打造公众链接感强的品牌项目，支持罕见病问题的制度保障，使每一个生命个体无论身患何种疾病、面临何种不便，都能获得尊重与善意，共同实现公平正义、多元共融的美好社会。   子评选-2025福布斯中国行业发展ESG标杆 2025福布斯中国行业发展ESG标杆颁奖现场   福布斯中国集团商务运营总经理郭隽祎，沙利文合伙人兼中东、南亚、北非区总裁Robin Joffe共同为2025福布斯中国行业发展行业发展ESG标杆平安健康医疗科技有限公司代表颁奖。   ● 公司介绍 ：平安健康医疗科技有限公司（股票简称：平安好医生，1833.HK），成立于2014年，是平安集团医疗养老生态圈的旗舰。公司于2018年5月4日在港交所挂牌上市，2020年7月获准纳入恒生科技指数。   凭借丰富的保险及金融客户端、企业端等医疗健康服务的支付方资源、广泛的服务供应商网络、完善的服务标准体系、强大的平安生态资源等核心竞争优势，平安健康深化落地管理式医疗战略，深耕“家庭医生”、“养老管家”两大核心枢纽建设，已成为专业、全面、高品质、一站式的医疗健康养老管理服务提供商。   子评选-2025福布斯中国行业发展创新品牌 2025福布斯中国行业发展创新品牌颁奖现场   福布斯中国集团商务运营总经理郭隽祎，沙利文合伙人兼中东、南亚、北非区总裁Robin Joffe共同为2025福布斯中国行业发展创新品牌科源制药代表颁奖。   ● 公司介绍 ：山东科源制药股份有限公司（301281.SZ）是国家高新技术企业、力诺集团健康产业核心成员企业、山东省化学合成药物骨干企业，致力于化学原料药产品研发、生产与销售以及国际高端CMO/CDMO业务的开发，与国际多家知名企业建立了战略合作伙伴关系。公司目前已经获得国内GMP证书、欧盟CEP证书，通过了美国FDA、加拿大、日本、韩国等国际官方认证。主要产品有盐酸二甲双胍、格列齐特、单硝酸异山梨酯、硝酸异山梨酯、盐酸罗哌卡因、乳糖酸克拉霉素、兰索拉唑、甲钴胺等，逐渐形成了降糖类、心血管类、麻醉剂类、抗肿瘤类、精神类等五大类药物并举的产品格局，为公司未来发展注入新的活力。公司拥有较为完善的生产、研发体系。生产厂区位于济南市商河县开发区，占地200余亩。公司研发拥有省级认定企业技术中心、市级博士后创新实践基地，拥有一支专业型、国际化的研发团队。 “致力于成为优秀的化药制造商”，科源制药始终秉承力诺集团“产业报国，追求卓越”的企业使命，在保持公司传统产品稳定增长的同时，大力发展CMO/CDMO业务，着力推进特色原料的产业布局，将科源制药打造成为国内一流、国际有影响力的公司，为人类健康事业做出更大贡献。   盛典精彩回顾 2025福布斯中国行业发展领创者评选荣耀盛典在沪隆重举行

In recent years, the boundaries between industry leaders and innovators have become increasingly blurred. These companies, leveraging their resource and market share advantages, as well as close collaboration with many startups or development teams, are gradually becoming important platforms for the commercialization of new technologies and business models. At the same time, relying on cutting-edge technologies such as artificial intelligence and big data, as well as innovative business concepts, more and more industry giants are unleashing unprecedented innovation vitality and stronger industry resource integration capabilities, enabling them to lead industry iterations and upgrades more efficiently. As a result, the concept and practice of industry development leaders are gradually emerging and will play an increasingly important role in leading the future industrial pattern transformation in China and even globally. With this understanding as a premise, at the end of November 2024, Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') and Forbes China jointly launched the '2025 Forbes China Industry Development Leaders Selection'. The selection focuses on key areas such as AI technology, mass consumption, biomedicine, new energy, finance, internet services, etc. Leveraging the top resources and professional teams of both parties in industry research and media dissemination, through rigorous data analysis and in-depth market research, it aims to identify and commend outstanding enterprises and individuals with broad influence and innovative spirit in China and even globally. Adhering to the principles of fairness, justice, and openness, on March 21, 2025, the evaluation committee meeting of the '2025 Forbes China Industry Development Leaders Selection' kicked off at the J Hotel in the Shanghai center. Thus, the months-long evaluation work of the '2025 Forbes China Industry Development Leaders Selection' has been successfully completed. The following are the final selected enterprises and individuals for the '2025 Forbes China Industry Development Leaders Selection':

Frost & Sullivan On March 22, 2025, the '2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Development Selection Gala Evening of Honor', co-hosted by Frost & Sullivan (Frost & Sullivan, abbreviated as 'Frost & Sullivan') and Forbes China, was successfully held at the Shanghai Seagull Lijing Hotel. This grand event brought together more than 200 leaders from politics, business, academia, industry-leading enterprises, and investment institutions, creating a stage for in-depth exchanges and intellectual collisions. It not only promoted cross-industry cooperation, inspired new business ideas, but also praised the pioneering entrepreneurial spirit from a unique perspective. At the same time, it outlined a common vision for the future development of industries with the greatest investment potential. The event kicked off with speeches by Aroop Zutshi, Global Partner and Executive Director of the Board at Frost & Sullivan; Professor Wang Yu, Expert Advisor to the Evaluation Committee and President of the China Foundation for the Prevention and Control of Hepatitis; Dr. Wang Xin, Global Partner and Chairman of Greater China at Frost & Sullivan; and Graham Earnshaw, Chief Strategy Officer of Forbes China Group. Zu Yarou, Global Managing Partner and Executive Director of the Board at Frost & Sullivan Aroop Zutshi, Global Managing Partner and Executive Board Member of Frost & Sullivan   The following are the key points of speech by Aroop Zutshi: Ni Hao and a very warm welcome to all of you. On behalf of the Board of Directors of Frost & Sullivan, my fellow partners, Dr. Neil Wang and my entire team in China, I welcome you to our inaugural event hosted in collaboration with Forbes. Thank you for taking the time to come and join us today. I wanted to share a few insights for all of you in the audience, which is focused around transformation. I think we saw in the past year that there has been massive transformation happening and coming. I would encourage companies to understand this transformation, and prepare for it. To overcome this challenge, we will significantly collaborate and partner in the future. This trend will continue to increase exponentially in the coming days, months and year. Hello everyone! On behalf of the Frost & Sullivan Board of Directors, my partner Dr. Wang Xin, and all members of our China team, I would like to warmly welcome you to the 2025 Frost & Sullivan China Entrepreneurship Annual Conference and the Forbes China Industry Development Pioneer Awards Ceremony. Thank you all for taking the time to attend! Today, I would like to share with you insights on "change" — we are living through a global upheaval.   One thing I want to make sure everyone knows is that this transformation is happening globally. Every part of the world is experiencing this change, no matter the industry, no matter the size of the company, no matter the region of the world. This transformation is coming and it's coming at a very fast pace. As an industry consultant and an industry research company, we have been monitoring the reasons, impact, and duration of this transformation. There are 8 strategic imperatives causing this effect. They are related to technology disruptions. We have seen technologies like Artificial Intelligence, quantum computing, data warehousing, etc., all playing a very significant role in how and what we are going to do in the future. We have also seen massive megatrends that are changing the global landscape. These trends are no longer localized; they are global in nature and will impact us in every direction. Similarly, there are huge changes happening in business models. New business models are coming into practically every industry we serve. It is no longer just happening in the business-to-consumer segment; it is also in business-to-business. Therefore, when you look at all this transformation, you also have to understand the geo-political chaos that is impacting the world. You have all seen the impact of tariffs, etc., initiated by the new administration in the US. This will mean new market alliances, new supply chains, etc., that companies will have to consider for the future. This will not stop in the near future. However, with all these transformations, we see new and powerful opportunities emerging before us. These opportunities have always been key to growing economies for governments and business growth for corporates and investors worldwide. Regardless of enterprise size, industry attributes, or location, this transformation is reshaping the world landscape at an astonishing pace. Industry transformation and collaboration have already occurred and are becoming future trends. As industry consultants and research institutions, we have been tracking their motivations, impacts, and cycles deeply, and have identified several strategic factors driving this transformation:   Technological Revolution: Technologies such as artificial intelligence, quantum computing, and data warehousing are profoundly reshaping future strategic directions and execution paths; Globalization super-trend: The once regional development momentum has evolved into global linkage; Business model iteration: From B2C to B2B and then back to B2C, with underlying business logic changing; Geopolitical Impact: Triggered by the new US tariff policy, tariff barriers have led to emerging market alliances and supply chain migrations.   So, for every company here, I would say, take advantage of this transformation, take advantage of this change, because change opens up new opportunities that you've never seen before or in the past. Just AI alone will open up so many different opportunities for us in our current business, including new ones in the short term. These changes will not stop at the present, but the opportunities born out of the crisis are also unprecedented— for governments, this represents a new engine for economic growth; for businesses and investors, it is a strategic positioning battle in the reshaping of the global landscape.   What we are finding is that in order to come up with these new growth opportunities and leverage these opportunities, you have to look at innovation. You have to make innovation at the core of everything that you do in your business. Because innovation gives you hope and, in the process, allows you to tackle some of these big challenges, big issues that are plaguing every company in the world today. Let's make innovation the core of everything we do. Technology is ubiquitous. It's available to everyone in every part of the world. You can now take help of technology to solve the biggest challenges in the world. One thing I can tell you, having traveled to more than 85 countries in the world, worked with business and corporates worldwide, including with governments, I can tell you, people in this room and people across the country of China are in very, very good shape. Your economy, your country, has made significant progress when it comes to leveraging and implementing technology. I remember about 10 years ago, Dr. Neil Wang took me to Nanjing to set up our new office. In Nanjing, I saw two buildings that hosted young entrepreneurs that were building technology solutions by leveraging AI when most of the world did not understand the word artificial Intelligence, China was way ahead of the curve. This is a trend that you will see more and more in China. So, I tell everyone in this room, you are very fortunate. You as a country are doing very well, I believe the China's impact on the global economy will continue to be profound. Very recently, I was in Germany and I can tell you today, every automotive OEM in the world is amazed about the way the China automotive industry is developing. BYD is pretty much in every major European country. And they are showcasing how technology needs to be delivered in a car. They are setting up global standards. Every major automotive OEM is studying and learning from Chinese OEMs. So, what we are going to see is some significant development from companies in China in practically all industries. But one thing I do want to tell everyone in the audience, especially the entrepreneurs, that when you build solutions, you need to be part of an ecosystem. And those solutions must be solutions that are very unique that are simple to explain and that are scalable, that are powerful in terms of its social impact. There has to be a purpose. And this is very important. And I believe that in the future, every major entrepreneur, every major corporation in this part of the world, must also be involved in giving. For every business present here: in the face of challenges, innovation must be anchored—only by embedding innovation into the genes can we turn challenges into opportunities. I have visited 85 countries around the world and collaborated with businesses and governments from all corners. I can tell you that the people in this room, as well as the entire Chinese people, are very fortunate. As an economy and a country, we have made remarkable progress in utilizing technology. I remember about ten years ago, Dr. Wang Xin took me to Nanjing to witness young entrepreneurs using AI to build solutions. At a time when most people in the world did not understand artificial intelligence, China was already ahead of the curve. I believe that China's impact on the global economy will continue to be profound. Recently, I went to Germany where BYD has made significant development in Europe, and Chinese automakers have redefined global standards. This momentum is spreading to all industries.   In conclusion, I would like to congratulate every company that is being recognized today. I want to thank all our panel of judges who spent an incredible amount of time going through a great deal of detail about your company's metrics, about your achievements, and then finally selecting the companies that will be recognized here today. Therefore, I would like to make a special recommendation to the entrepreneurs present: when building solutions, please integrate ecosystems, focusing on uniqueness, scalability, and social value. Future leading enterprises will inevitably be practitioners of business in alignment with goodness.   Finally, I would like to thank Forbes for partnering with Frost & Sullivan. We have Graham from Forbes here, collaborating with us, and bringing something valuable to this audience and to our country, which I believe will be a significant driver in the industry development you saw earlier on the slide. So, with that, I would like to welcome you all once again. Have a wonderful time. Thank you very much. And I look forward to connecting with all of you as the day progresses. Xie Xie. Finally, congratulations to all the award-winning companies! We would like to thank the judging panel for their professional dedication. It was their hours of careful review that led to today's award-winning colleagues. We also want to express our gratitude to our partners: Forbes China, especially Mr. Yan Gewen who is present today and has provided strong support. Let us work together to advance the industry! Thank you all again for coming and joining us in this grand event. At the same time, we look forward to having in-depth exchanges with you. Thank you! Professor Wang Yu, Expert Advisor of the Evaluation Committee and President of the China Hepatitis Prevention and Control Foundation Wang Yu, Chairman of the Chinese Foundation for Hepatitis Prevention and Control   The following are the key points of Professor Wang Yu's speech: Distinguished entrepreneurs and experts, good afternoon! Distinguished entrepreneurs and experts, good afternoon!   On behalf of the expert panel, I would like to speak on behalf of the Frost & Sullivan China Industry Development Leaders Selection Organizing Committee and with the trust of the judging experts. On behalf of the Forbes and Frost & Sullivan China Industry Development Leaders Selection Committee, and with the trust of the judges, I am honored to deliver a speech on behalf of the panel of judges.   The selection experts from multiple fields are industry leaders. They listened attentively to the performance introductions of each shortlisted entrepreneur by the recommendationers and highly recognized the entrepreneurs' struggle and achievements. The judges, who come from various fields and are all leading figures in their respective industries, have carefully listened to the introductions of the achievements of each shortlisted entrepreneur. We highly recognize the entrepreneurial journeys and accomplishments of these individuals.   We believe that the '2025 Forbes China Industry Development Leaders' selection has very positive practical significance. China is a major manufacturing country in the world, renowned for its comprehensive and richest industrial chain, including both traditional and emerging industries. Looking at the industries of the recommended entrepreneurs, there are those in biomedicine, new energy, information technology, as well as catering, logistics, pet care, consulting, and even a cryo-electron microscopy service center dedicated to structural biology research. It can be said to represent the pinnacle of high-tech service industries. There are only things that are unimaginable and unattainable; there are no products or services that cannot be bought or ordered. These entrepreneurs are like pearls on the industrial chain, shining on their own and representing and leading the innovative development of various industries. We believe that the 2025 Forbes China Pioneer Innovators in Industry Development Selection has very positive and practical significance. China is a global manufacturing powerhouse, renowned for its comprehensive and diverse industrial chains, which include both traditional industries as well as emerging ones. Looking at the industries of the nominated entrepreneurs, we see a wide range, from biopharmaceuticals, new energy, and information technology to the catering industry, logistics, pet services, consulting, and even specialized services like cryo-electron microscopy centers for structural biology research, which represent the pinnacle of high-tech service industries. In China, there is nothing that cannot be bought or ordered virtually; the only limitations are imagination and knowledge. These entrepreneurs are like pearls on various industrial chains, each shining brightly while representing and leading the innovative development of their respective industries.   It now appears that simply ranking entrepreneurs by their wealth does not fully reflect the innovative, developmental, and growth characteristics of these industries and services, especially their trend-setting and leading qualities. More elements should be used to describe, reflect, and evaluate them. This is because it is a world-class and historic phenomenon. It now appears that ranking entrepreneurs solely by their wealth cannot fully reflect the characteristics of innovation, development, and growth potential of these industries and service sectors, especially their trend-setting and leading nature. A more comprehensive set of criteria is needed to describe, reflect, and evaluate these phenomena, as this is a world-class and historic occurrence.   The Forbes and Frost & Sullivan jointly conduct the China Industry Development Pioneer Awards, which possess undisputed authority, seriousness, and a solid business foundation. Forbes and Frost & Sullivan's joint initiative to conduct the China Pioneer Innovators in Industry Development Selection is undoubtedly authoritative, highly rigorous, and backed by a strong foundation in expertise.   Although today's society has seen very active and surging waves in cutting-edge technology industries such as AI, new energy, biomedicine, and new materials, which are changing rapidly, there are still deep and stable basic needs in human society that are becoming more profound. For example, the pursuit of survival, health, and longevity requires various industrial chains represented by the service industry. Despite the fact that today's society is witnessing very active and surging waves of innovation in frontier technology industries such as AI, new energy, biopharmaceuticals, and new materials, which are constantly changing, there are still deep and stable fundamental needs in human society that are becoming increasingly profound, such as the pursuit of survival, health, and longevity. These needs are supported by various industrial chains, represented by the service sector.   Medicine is very much about pursuing cutting-edge research, but for anyone suffering from a particular disease, no medical specialty is a minor field that does not require development and innovation. In hospitals, it is not only the oncology department that is important; if you have skin disease, the dermatology department is important; if you have eye problems, the ophthalmology department is important. Medicine may pursue the cutting-edge, but for any individual suffering from a particular disease, no medical specialty is a minor department that does not require development and innovation. In a hospital, it is not just the oncology department that is important. If you have a skin disease, the dermatology department is crucial. If you have an eye condition, the ophthalmology department is vital.   Innovation, leadership, and growth are the tenets of the industry development leader selection, aimed at encouraging and promoting the extension and strengthening of the industrial chain, and driving industry development is the original intention of the selection. It is hoped that the selected individuals will continue to carry forward the spirit of innovation and growth, leading the industry to continuous development. Innovation, leadership, and growth are the tenets of the Forbes China Pioneer Innovators in Industry Development Selection. Encouraging and promoting the extension and strengthening of industrial chains and driving industry development are the original intentions of this selection. We hope that the selected individuals will continue to carry forward the spirit of innovation and growth and lead the continuous development of their industries.   Wish the selection activity for industry leaders in China continues to improve, expanding its influence day by day, and becoming a descriptor and promoter of industry development in China. We wish the Forbes China Pioneer Innovators in Industry Development Selection continued improvement and expansion of its influence, becoming a descriptor and promoter of China's industry development.   I would like to take this opportunity to express another perspective from the standpoint of the China Hepatitis Prevention and Control Foundation. Entrepreneurs interact with social consumers through their products, Forbes assesses entrepreneurs' wealth, while Frost & Sullivan participates in corporate and social interactions through professional consulting. In today's era of Made in China and service development, there is also an important aspect: the social responsibility of enterprises, including public welfare and charitable activities. The China Hepatitis Prevention and Control Foundation serves as a bridge and messenger of love between entrepreneurs and the vast number of liver disease patients in our country. Entrepreneurs who are concerned about the burden of hepatitis and related diseases in our country are welcome to discuss any good deeds aimed at aiding liver disease patients and alleviating their suffering with the hepatitis foundation. Taking this opportunity, allow me to express another sentiment from the standpoint of the China Hepatitis Prevention and Control Foundation. Entrepreneurs interact with consumers through their products, Forbes assesses entrepreneurs' wealth, and Frost & Sullivan facilitates the interaction between enterprises and society through professional consulting. In today's era of China's manufacturing and service development, there is another important aspect: corporate social responsibility, philanthropy, and charitable activities. The China Hepatitis Prevention and Control Foundation serves as a bridge and messenger of compassion between entrepreneurs and the vast number of patients with liver diseases in our country. We warmly welcome entrepreneurs who are concerned about the burden of hepatitis and related diseases in China to discuss any benevolent actions with the foundation to help alleviate the suffering of patients with liver diseases.   Thank you to Forbes, Frost & Sullivan, and all the judging experts! Thank you, Forbes, Frost & Sullivan, and all the judges!   Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan Greater China Region Neil Wang, Frost & Sullivan Global Partner and Chairman of Greater China   The following are the key points of Dr. Wang Xin's speech: Distinguished guests, ladies and gentlemen: Hello everyone! Distinguished guests, ladies and gentlemen,   Welcome to the 2025 Frost & Sullivan China Entrepreneurs Annual Conference. First of all, on behalf of Frost & Sullivan, I would like to extend my warmest welcome and heartfelt gratitude to every guest present here! Thank you all for taking the precious time off this weekend to come from all over the world to share our glory, to reminisce about old friendships and forge new ones across industries with us. It is my great honor to welcome you to the 2025 Frost & Sullivan China Entrepreneurs Annual Conference. On behalf of Frost & Sullivan, I would like to extend my warmest greetings and heartfelt gratitude to all of you. Thank you for taking the time to join us from across the world, especially on a weekend, to celebrate excellence, foster friendships across industries, and explore new opportunities for collaboration and growth.   This year's Frost & Sullivan Entrepreneurs Annual Conference is particularly valuable for several reasons. Firstly, it is due to our strategic partnership with Forbes China, which has brought together the top resources and professional teams from both sides in the fields of industry research and media communication, creating a new selection project called 'Industry Development Leaders'. Secondly, it is because the 100 'leading' companies that will gather at the event today make the 'annual gathering' truly a celebration of 'full confidence'. This year's Frost & Sullivan Entrepreneurs Annual Conference is particularly significant. Firstly, it marks the launch of an exciting new initiative, the 'Pioneer Innovators in Industry Development' project, born from our strategic partnership with Forbes China. This groundbreaking collaboration combines Frost & Sullivan's unmatched expertise in industry research with Forbes China's legacy of leadership in media and global influence, showcasing a shared commitment to identifying and empowering transformative leaders. Secondly, today's gathering brings together 100 of the most pioneering and innovative companies, making this event not only an annual meeting, but a dynamic celebration of confidence in the future of business.   Both Frost & Sullivan and Forbes China Group are industry-leading institutions with a global perspective and a long-term commitment to deeply cultivating the Chinese market. Frost & Sullivan has been involved in industry research for over 60 years, enjoying a high reputation in global capital markets for its in-depth industry insights, rigorous data analysis, and professional consulting services. Forbes China, with its century-long heritage, discovers emerging leaders from a unique perspective, inspiring countless hardworking individuals to pursue their dreams. Both Frost & Sullivan and Forbes China are organizations with a global outlook and a deep commitment to the Chinese market, each recognized as a leader in its respective field. For over 60 years, Frost & Sullivan has been a trusted authority in industry research, renowned for our rigorous data analysis, actionable insights, and strategic advisory services that have earned us a stellar reputation in global capital markets. Forbes China, with its century-old heritage, is celebrated for its ability to identify emerging leaders and inspire entrepreneurs to pursue their ambitions.   This collaboration with Forbes China allows us to observe the trajectory of business growth and document the evolution of industries through vivid “individuals” entrepreneurs. This not only enriches the Frost & Sullivan 'Full-Service Investment Management' ecosystem but also enables us to showcase more outstanding Chinese industry development leaders to the world. It further unleashes the long-term influence and infinite possibilities of Frost & Sullivan's nearly 30 years of continuous focus on growth, innovation, and leadership best practices. This partnership with Forbes China allows us to explore the evolution of business and industry through the inspiring stories of remarkable individuals. It enriches Frost & Sullivan's "Total Investment Management" ecosystem and enables us to present a more vivid and compelling narrative of China's Pioneer Innovators in Industry Development to the global stage. At the same time, it reinforces Frost & Sullivan's nearly three decades of commitment to promoting growth, technological innovation, and leadership excellence in China.   Looking ahead, the tide of technology is surging, and market patterns are changing rapidly. However, no matter how times change, the entrepreneurial spirit remains one of the core forces driving social progress. Looking ahead, the rapid advancement of technology and the ever-changing dynamics of global markets will continue to define the business landscape. Yet, through all this change, one constant remains: entrepreneurship. It is, and always will be, one of the driving forces behind societal progress and economic transformation.   Frost & Sullivan is optimistic about China and the future, especially about the bright prospects for the development of Chinese enterprises. We believe that the exemplary leadership of our pioneers will surely lead the Chinese economy to create more glories on its new journey! Frost & Sullivan is deeply optimistic about China's future and the bright future of Chinese enterprises. We firmly believe that the pioneering and innovative efforts of leaders gathered here today will continue to set benchmarks for success and lead China's economy to unprecedented heights.   Congratulations again! Thank you! Once again, congratulations to all of you for your achievements and thank you for being part of this extraordinary gathering.   Yan Gewen, Chief Strategy Officer of Forbes China Group Graham Earnshaw, Chief Strategy Officer of Forbes China Group   The following are the key points from Graham Earnshaw's speech: Distinguished guests: Good day! Distinguished guests, Hello, everyone!   I am Graham Earnshaw, Chief Strategy Officer of Forbes China Group. On behalf of Forbes China Group, I would like to express our gratitude to all of you for attending this event! At the same time, I am also very grateful to Frost & Sullivan for their strong support for this event and for their efforts in the launch and advancement of the '2025 Forbes China Industry Development Leaders Selection'. I am Graham Earnshaw, Chief Strategy Officer of Forbes China Group. On behalf of Forbes China Group, I would like to express our sincere gratitude to everyone for attending this event today. We would also like to extend our heartfelt thanks to Frost & Sullivan for their strong support for this event and for their efforts in the launch and advancement of the "2025 Forbes China Pioneer Innovators in Industry Development Selection."   Today, we gather here with China's most outstanding entrepreneurs and leaders from various industries. Taking this opportunity, we can discuss together about corporate growth and industry development. We have just entered 2025 after a challenging 2024, especially in the past two months or so, when we have experienced more profound and complex changes. On one hand, geopolitical conditions are becoming more volatile, and the pace, extent, and uncertainty of economic globalization adjustments have exceeded expectations; on the other hand, domestic investment and financing, domestic demand, market confidence, etc., in China need more vigorous stimulation and improvement. Moreover, at the recently held 'Two Sessions', the urgency of technological innovation and industrial innovation has also received more attention. Today, we gather here with the most outstanding entrepreneurs and industry leaders from across China. This is an opportunity for us to jointly explore business growth and industry development. We have just moved from the challenging year of 2024 into 2025, and especially in the past two months, we have experienced more profound and complex changes. On one hand, geopolitical situations have become more volatile, with the speed, extent, and uncertainty of the adjustment of economic globalization exceeding expectations. On the other hand, China's domestic investment and financing, domestic demand, and market confidence all require more vigorous stimulus and improvement. The urgency of technological and industrial innovation was also highlighted more prominently at the recently held The Two Sessions of the NPC and the CPPCC.   Currently, challenges from global ecological and business trends are intensifying. These challenges are not only at the enterprise level but also at the industry level—changes in industries and markets are even faster than before. Historical experience tells us that enterprises that can grasp industry changes, especially those that can lead the industry to continuous breakthroughs and innovation, will reap unimaginable benefits. Currently, challenges from global ecological and business trends are intensifying. These challenges are not only at the corporate level but also at the industry level— the pace of industry and market changes is even faster than the pace of corporate changes in the past. Historical experience has taught us that companies that can grasp industry changes, especially those that can lead industries to continuous breakthroughs and innovations, will reap unimaginable benefits.   On this extremely critical stage, we look forward to seeing outstanding entrepreneurs, especially leaders in various industries, exert greater leadership and innovation, and demonstrate more industry responsibility and social commitment. Today, Forbes China is very honored to be with you to discuss the challenges and opportunities we all face together. We hope everyone can speak freely and share valuable perspectives and ideas. At this extremely critical stage, we expect our outstanding entrepreneurs, especially the leaders of various industries, to exercise greater leadership and innovation, and to demonstrate more industry responsibility and social commitment. Today, Forbes China is honored to be here with all of you to discuss the challenges and opportunities we face together. We hope everyone will speak freely and share their valuable insights and ideas.   Thank you all! Thank you all!   In addition, Dr. Wang Xin delivered a welcome speech for the 2025 Forbes China Industry Development Leaders Selection Honors Ceremony. Dr. Wang Xin, Global Partner and Chairman of Frost & Sullivan Greater China Region Neil Wang, Frost & Sullivan Global Partner and Chairman of Greater China   The following are the key points of Dr. Wang Xin's speech: Distinguished guests, ladies and gentlemen: Good evening! Distinguished guests, ladies and gentlemen,   Welcome everyone to Shanghai, an international metropolis with the spirit of "embracing all rivers and pursuing excellence." By the Pujiang River, we will jointly witness the grand event of the 2025 Forbes China Industry Development Leaders Selection. First of all, please allow me on behalf of the selection organizers—Frost & Sullivan—to extend our most sincere gratitude and warmest welcome to all entrepreneurs and all the guests present! Welcome to Shanghai, a vibrant international metropolis renowned for its spirit of inclusivity and pursuit of excellence. Tonight, by the banks of the Huangpu River, we gather to witness the grand celebration of the 2025 Forbes China Pioneer Innovators in Industry Development Awards. First and foremost, on behalf of the organizers—Frost & Sullivan—we would like to extend our deepest gratitude and warmest welcome to all the entrepreneurs and distinguished guests present here tonight.   The words 'lead' and 'create' may seem simple, but they contain profound meanings and power. The two words, "Pioneer" and "Innovation," may seem straightforward, but they carry profound significance and immense meaning.   In an era where technology is changing rapidly, entrepreneurs who can lead trends, dominate industries, and steer the future are not only at the forefront but also the pillars of society. In this era of rapid technological advancement, entrepreneurs who lead trends, shape industries, and navigate future opportunities are not only the leaders of their fields but also the pillars of progress.   In the face of an extremely competitive market, entrepreneurs who can continuously break through in technology, product, model, management, and other aspects to achieve differentiated success and continuously inject new vitality and momentum into the market are trendsetters as well as disruptors. In the face of increasingly competitive markets, those who continuously break through in areas such as technology, products, business models, and management, and achieve distinctive success while injecting fresh vitality and new momentum into the market, are both pioneers and groundbreakers.   In recent years, industry leaders and innovators have continuously crossed boundaries and integrated with each other, giving rise to new productivity and possibilities. Resources and technologies coexist and win-win situations are created, constructing an anticipated future industrial landscape. In recent years, industry leaders and innovators have increasingly transcended boundaries, driving new sources of productivity and possibilities. Through the synergy of resources and technologies, they have created a promising vision of future industries where collaboration and mutual success flourish.   "Leading" and "creating" are precisely the epitome of the vibrant entrepreneurial spirit in China. Tonight, entrepreneurs share a common name—leaders and creators; and we are honored to give a thumbs up to these 55 vivid interpretations that embody this resounding title! "Pioneer" and "Innovation" are indeed the most vivid expressions of entrepreneurship in China. Tonight, every entrepreneur here shares a common title: Pioneer Innovators. And we are deeply honored to celebrate the 55 diverse and inspiring representations of that title.   Now, let us raise our glasses together to congratulate all the pioneers in Forbes China's industry development! Pay tribute to you! We wish that in your future endeavors, you will continue to lead the industry, create value, bravely take on responsibilities, and contribute 'pioneering' strength to the vigorous development of China's economy! Now, let us raise our glasses together to congratulate all the Forbes China Pioneer Innovators in Industry Development! We wish you continued success in the future, as you lead industries, create value, and shoulder responsibilities, contributing your trailblazing power to the vibrant development of China's economy.   Cheers! Thank you all! Cheers! Thank you all!

Insights from Frost & Sullivan In 2024, multiple departments including the Ministry of Industry and Information Technology issued documents encouraging the development of brain-computer interfaces (BCIs). Recently, Beijing, Shanghai, and other places have also intensively released action plans related to BCIs. How do you view the impact of policies on the BCI industry and enterprises in the past two years? What are the obvious changes in BCI policy levels in the past two years, from ministerial policies to local specific policies? From a professional perspective, which aspects of the policies are particularly worthy of attention? Why? Is healthcare the first area where BCIs will be implemented? How do you view the development potential of BCIs in the medical field?   Zhou Mingzi, Executive Director of Frost & Sullivan Greater China, was interviewed by The Paper to discuss policy support and application prospects for the BCI industry. The Paper *Click on the end of the article Read the original article for a complete report   Q: In 2024, multiple departments including the Ministry of Industry and Information Technology issued documents encouraging the development of BCIs. Recently, Beijing, Shanghai, and other places have also intensively released action plans related to BCIs. How do you view the impact of policies on the BCI industry and enterprises in the past two years? What are the obvious changes in BCI policy levels in the past two years, from ministerial policies to local specific policies?   Zhou Mingzi Executive Director of Frost & Sullivan Greater China In recent years, policy support for the BCI industry has gradually strengthened, especially with documents issued by multiple departments such as the Ministry of Industry and Information Technology, encouraging and promoting the development of this cutting-edge technology. From a macro perspective, the introduction of policies not only points out the direction for the industry but also provides a clear regulatory framework and financial support. The government has reduced the cost of enterprise research and development through measures such as setting up special funds and tax incentives, increasing the enthusiasm for technological innovation. This is particularly important for start-ups in the BCI industry, not only accelerating the commercialization process of BCI technology but also providing clear development paths and confidence for related enterprises, promoting the gradual improvement of the industrial ecosystem.   From ministerial policies to local policies, there have been obvious changes in BCI policy levels. Ministerial policies focus more on macro-level technological breakthroughs and industrial layout, such as promoting the establishment of a BCI standardization technical committee. Local policies are more targeted, emphasizing the implementation of specific technical paths and the expansion of application scenarios, shifting the focus from the 'exploration phase' to the 'implementation phase' of BCI technology.   Q: The Shanghai action plan on BCIs not only sets future industry development goals but also provides specific support policies in five areas: accelerating BCI productization, building a common technology R&D service platform, promoting clinical trials and application demonstrations, improving product standards and testing systems, and cultivating an industrial innovation ecosystem. From a professional perspective, which aspects of the policies are particularly worthy of attention? Why?   Zhou Mingzi Executive Director of Frost & Sullivan Greater China Among the above directions, policies in accelerating BCI productization and building a common technology R&D service platform are particularly noteworthy. First, the acceleration of productization will directly determine whether technology can truly be implemented and meet market demand. Especially since BCI technology is still in a relatively preliminary stage, how to transform research and development achievements into commercially viable products is a key challenge faced by enterprises. Second, building a common technology R&D service platform can effectively reduce repetitive investment in technology R&D, promote collaborative innovation upstream and downstream of the industrial chain, help enterprises quickly break through technical bottlenecks, and enhance the competitiveness of the overall industry. These favorable policies will help create a healthy environment for technological innovation and industrialization, promoting the rapid development of the BCI industry.   Q: BCIs are considered to have great potential in multiple areas such as healthcare, education, and entertainment. Is healthcare the first area where BCIs will be implemented? How do you view the development potential of BCIs in the medical field?   Zhou Mingzi Executive Director of Frost & Sullivan Greater China The healthcare field is indeed one of the areas where BCIs are most likely to be implemented first. The application of BCI technology in healthcare, especially in neuroscience and rehabilitation medicine. With continuous technological breakthroughs, BCIs can provide unprecedented treatment methods to help restore or replace patients' lost functions. For patients with neurological diseases such as stroke, spinal cord injury, ALS (amyotrophic lateral sclerosis), and Parkinson's disease, BCI technology can improve patients' motor ability, cognitive function, and quality of life by directly reading brain signals or stimulating specific areas of the brain. In addition, BCIs also show certain potential in the field of mental health, providing new ideas for the diagnosis and treatment of mental illnesses through monitoring brain waves. With the maturity of technology, cost reduction, and improvement of regulatory environments, BCIs will gradually transform from clinical trials to widespread application in the medical field, becoming an important tool for improving global health levels.   Q: Globally, companies under Elon Musk are receiving much attention for their exploration of BCIs, and there has also been progress domestically. Based on current progress, what stage is China's BCI technology or industry in? Is it in a leading position globally?   Zhou Mingzi Executive Director of Frost & Sullivan Greater China Currently, China's BCI industry is continuously breaking through the budding stage and striving towards a rapidly developing stage, especially making significant progress in basic research, technological breakthroughs, and industrial application. Although domestic technology still has a certain gap compared to global leading levels, China's investment and innovation in related fields are gradually catching up, especially in some specific application scenarios such as healthcare. In addition, government policy support for the BCI industry is gradually increasing, and the introduction of funds and talents also provides strong impetus for industrial development.   Globally, although China has made breakthroughs in some fields and applications, it is not in a completely leading position overall. Companies like Neuralink under Musk, with huge financial support and technical accumulation, are still at the forefront of global BCI technology. China needs to further strengthen technological innovation, especially in core technology independent research and development, standard setting, interdisciplinary integration, etc., to effectively catch up with and surpass global leading positions.   Q: What challenges may lie ahead for the future development of domestic BCIs? For example, are they breakthroughs in basic research or commercial implementation scenarios, or issues related to the payment side?   Zhou Mingzi Executive Director of Frost & Sullivan Greater China The challenges for the future development of domestic BCIs are mainly reflected in several aspects. First, breakthroughs in basic research remain the core bottleneck. The accuracy, stability, and safety of BCI technology still need to be further improved, especially in high-complexity neural signal decoding and real-time response. Second, although domestic research and development have made certain progress, there are still challenges from laboratory to commercial application implementation, especially in how to transform BCI technology into products and services that are popular and meet practical needs.   In addition, issues related to the payment side cannot be ignored. The high technical threshold and R&D costs of BCIs mean that enterprises need to invest a large amount of capital, while user acceptance and willingness to pay in the market are still forming. How to balance high costs and user payment capabilities is a major challenge in the industrialization process. Finally, policy supervision and ethical issues are also important factors restricting the widespread application of BCI technology. How to ensure safety and ethical legitimacy while ensuring technological innovation will be an important challenge in the future development. *This interview has been published in The Paper by reporter Li Xiaoxiao, with the original title: The BCI Market Welcomes Good News, Beijing and Shanghai Announce Action Plans One After Another, What Challenges Remain?  

The 2nd New Investment Expo 2023 and the 17th Frost & Sullivan Global Growth, Innovation and Leadership Summit were held again at the 'World Salon' in Shanghai from September 27th to 28th, 2023. On September 28th, the 2023 Frost & Sullivan Global Awards for Growth, Innovation and Leadership, Asia-Pacific and China were grandly announced at the Frost & Sullivan Life Sciences New Investment Summit Forum.   Based on recent research and analysis of China's digital healthcare marketing and physician platform markets, as well as studies and evaluations of related companies in the industry, the globally renowned growth consulting firm Frost & Sullivan (Frost & Sullivan, abbreviated as Frost & Sullivan) awarded Shanghai Meis Medical Technology Co., Ltd. (hereinafter referred to as 'Meis Medical') the 'China Digital Marketing Leadership Award', which was presented by Dr. Wang Xin, a global partner and Chairman of Greater China at Frost & Sullivan, to Mr. Fan Jie, Co-CEO of Shanghai Meis Medical Technology Co., Ltd. Frost & Sullivan awarded Meis Medical the 'China Digital Marketing Leadership Award' Dr. Wang Xin presented the award to Mr. Fan Jie, Co-CEO of Meis Medical   One of the largest online professional physician platform operators in China Meis Medical was established in 2012 and is headquartered in Shanghai, China. As one of the largest online professional physician platform operators in China, Meis Medical uses big data and artificial intelligence technologies to connect doctors, patients, and pharmaceutical and medical device enterprises, empowering the healthcare ecosystem and improving healthcare quality.   Its services include physician platform solutions, real-world research solutions, precision omnichannel marketing solutions, APO innovative digital marketing solutions, and hospital digital research platform solutions, covering pharmaceutical marketing consulting, medical affairs empowerment, multi-channel academic dissemination, and other specialty services. It provides pharmaceutical and medical device enterprises with one-stop digital solutions for medicine, market access, and dissemination. Meis Medical's medical expertise and research support capabilities are highly recognized in the industry, and it has been empowered by cutting-edge technologies such as big data and artificial intelligence, enabling it to quickly perceive and capture industry trends in R&D and collaboratively promote the efficient development of various business segments.   Professional content output for physician platforms, safeguarding the development of physicians at all stages of their careers The Meis Doctor Platform provides professional content push for physicians, medical institutions, as well as healthcare professionals and life science professionals. Meis Medical's leading medical academic knowledge and research support capabilities have formed a unique influence barrier for the physician group in the industry. As of June 30th, 2023, the platform has approximately 3 million registered physician users, with an average monthly active user of about 2.8 million in 2023. Thanks to the professionalism of its content output and precise push targeting user research areas, users can obtain the latest developments in research fields from mobile and computer terminals in a timely manner, cultivating users' habit of using the platform. Registered physician users with associate chief physician or above titles on the platform account for about 72% of the latest statistics of associate chief physicians or above titles from the National Health Commission, achieving wide coverage for senior Chinese doctors. Senior doctors have a high influence in the healthcare ecosystem and can promote the approval of innovative pharmaceuticals and medical devices, conduct clinical trials to expand indications, explore optimized treatment methods for diseases, and use their influence for academic promotion.   Precision omnichannel marketing solutions, addressing industry pain points based on big data and professionalism Meis Medical's precision omnichannel marketing solutions can provide full-channel multi-modal precision marketing plans for all stages of the lifecycle of innovative drugs or medical devices. Traditional marketing has pain points such as high costs and limited reach, insufficient marketing content production capabilities, and low efficiency in medical decision-making. In contrast, digital methods can bring higher convenience to marketing and more accurate target group information delivery. Relying on the efficient driving ability of 'medical academia + digitalization' of the excellent doctor platform and strong professional content output capabilities, Meis Medical can fully explore the academic highlights of pharmaceutical products, analyze clinical application differences between different products, accurately match patients, enhance rationality in medication use, and fully reflect the clinical value of pharmaceutical and medical device products.   Real-world clinical research (RWS) solutions, helping with the post-marketing clinical application promotion of innovative drugs and medical devices Currently, there are mainly three types of RWS solutions, including RWS based on physician platforms, RWS based on CROs, and RWS based on big data. Compared with other categories, RWS based on physician platforms has the advantages of more flexible service plans and lower costs. Meis Medical's strong medical academic support team and professional project operation team can provide one-stop services for sponsors, including research strategy and plan design, full-process project operation management, consultation and statistical analysis by internal and external statistical experts, publication strategy and support for research results. In addition, RWS research results can reflect the application of pharmaceutical and medical devices in the real-world environment, assist in safety and effectiveness evaluation, expand the indication scope of pharmaceutical and medical device products and accelerate the commercialization process of products. Combined with Meis Medical's digital marketing capabilities, it can further accelerate the promotion of pharmaceutical and medical device products among the indicated population.   APO innovative digital marketing solutions, empowering innovative drugs to grow rapidly In response to industry pain points such as high commercialization costs and long cycles for innovative drugs and medical devices, Meis Medical's APO innovative digital marketing solutions provide three innovative service models: iDocEco Specialist Doctor Diagnosis and Treatment Collaboration Platform - precisely linking specialists in different disease areas across the country, efficiently promoting innovative drugs, and accelerating the expansion and penetration of innovative drugs; iPatFlow Patient Full Journey Management Service - providing convenient diagnostic tools, patient referral support, and innovative drug consultation services for doctors on the iDocEco platform. It helps doctors quickly screen and diagnose patients, enabling patients to obtain innovative drug treatment as early as possible; iMarkAcce Academic Marketing Accelerator - providing academic research topic services for experts on the iDocEco platform to verify the effectiveness and safety of innovative drugs, accelerating the understanding and familiarity of the unique clinical efficacy of innovative drugs by experts, and promoting standardized treatment.   Hospital digital research platform solutions, efficiently enhancing hospital clinical research capabilities and output Meis Medical has created a leading hospital clinical research empowerment product - the Hospital Digital Research Platform Solution, through its excellent medical academic capabilities, advanced medical big data technology, and rich clinical research service experience. The business covers the construction of the hospital's scientific research big data center, construction of specialized disease databases, real-world research, scientific research talent cultivation, refined scientific research management, clinical research services, and scientific research achievement transformation, providing one-stop solutions for hospitals to enhance their scientific research capabilities and promote achievement output.   About the 2023 Frost & Sullivan Life Sciences New Investment Summit Forum The 2023 Frost & Sullivan Life Sciences New Investment Summit Forum was held on September 27th - 28th with the theme 'New Directions for the Future & Forging Ahead'. It gathered more than 30 industry leaders, life science enterprises, investment institutions, and professional service institutions, focusing on new investment and financing opportunities in life sciences, and jointly discussing the capital and industrial forces for enterprises to navigate through cycles. About the Frost & Sullivan China Leadership Award The Frost & Sullivan China Leadership Award is an acknowledgment of an enterprise's outstanding performance and achievements in professional medical content output, market potential, customer service, brand, etc. The Frost & Sullivan team nominated a group of competitive outstanding enterprises to the independent judging panel through methods such as in-depth interviews, industry analysis, and secondary research. The independent judging panel composed of third-party investment and financing experts, financial experts, bankers, and well-known listed entrepreneurs conducted strict evaluations on the enterprises nominated by the Frost & Sullivan team and decided to award the 'China Digital Marketing Leadership Award' to Meis Medical.